RXi Pharmaceuticals

The momentum for this stock is not very good. RXi Pharmaceuticals has good value characteristics. RXi Pharmaceuticals is a mediocre stock to choose.
Log in to see more information.
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-on...
PHIO Fundamental Data by TradingView

News

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Newsfile Corp. - News Releases Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...\n more…

Phio Pharmaceuticals (NASDAQ:PHIO) Trading Down 0.8%
Phio Pharmaceuticals (NASDAQ:PHIO) Trading Down 0.8%

Zolmax Shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO - Get Free Report) were down 0.8% during mid-day trading on Friday . The company traded as low as $2.50 and last traded at $2.61. Approximately...\n more…

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Is Breakeven Near?
Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Is Breakeven Near?

Simply Wall St Phio Pharmaceuticals Corp. ( NASDAQ:PHIO ) is possibly approaching a major achievement in its business, so we would...\n more…

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile Corp. - News Releases Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...\n more…

Phio Pharmaceuticals (NASDAQ:PHIO) Issues Earnings Results, Beats Estimates By $0.97 EPS
Phio Pharmaceuticals (NASDAQ:PHIO) Issues Earnings Results, Beats Estimates By $0.97 EPS

Ticker Report Phio Pharmaceuticals (NASDAQ:PHIO - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($3.62) EPS for the quarter, beating the consensus estimate of ($4.59...\n more…

Short Interest in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Rises By 178.0%
Short Interest in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Rises By 178.0%

Zolmax Phio Pharmaceuticals Corp. (NASDAQ:PHIO - Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 16,400 shares, a growth of 178.0...\n more…